Developing safety criteria for introducing new agents into neoadjuvant trials.

Area of Science:

• Oncology
• Pharmacology
• Clinical Trial Design

Background:

• Drug development faces challenges in time, cost, and resource allocation.
• Neoadjuvant studies offer a strategy to accelerate drug development by testing agents earlier in disease progression.
• The U.S. Food and Drug Administration (FDA) supports neoadjuvant trials using pathologic response as a surrogate endpoint.

Purpose of the Study:

• To explore strategies for accelerating drug development through neoadjuvant studies.
• To address the unique challenges of patient safety in neoadjuvant settings.
• To present the I-SPY2 trial as a model for safe and efficient neoadjuvant drug development.

Main Methods:

• Utilizing pathologic response as a surrogate endpoint in neoadjuvant trials.
• Implementing adaptive trial designs to limit patient exposure to ineffective agents.
• Intensifying safety monitoring and risk assessment for investigational agents.

Main Results:

• Neoadjuvant studies can identify active agents and biomarkers more rapidly.
• Adaptive phase II designs can reduce the time and cost of screening novel therapies.
• The I-SPY2 trial successfully addressed safety concerns in neoadjuvant breast cancer drug development.

Conclusions:

• Neoadjuvant drug development, when carefully designed, can accelerate the identification of effective therapies.
• Patient safety is paramount and can be managed through rigorous trial design and monitoring.
• Adaptive phase II trials represent a valuable approach for efficient and safe drug development in oncology.